Abstract
Objective: The increase in resistance to gram positive organisms and seriousness of infective endocarditis, makes it necessary to look for an alternate treatment. Methods: In-vitro activity of synercid was compared with penicillin, amoxycillin, teicoplanin, vancomycin, clindamycin and erythromycin. Results: Synercid showed minimum inhibitory concentrations (MIC) within the narrow range of 0.06 – 0.5 mg/l. MIC50 and mode values were both 0.25 mg/l. There was just two-fold difference between the MIC50 (0.25 mg/l) and the MIC90, (0.5 mg/l). Although the MICs of synercid for S. oralis were relatively high compared to penicillin, clindamycin, erythromycin and teicoplanin, the in-vitro bactericidal activity of synercid was much greater. Synercid MBC values were < 4 mg/l for most of the isolates, except for one of 16 mg/l and the other >64 mg/l. Killing curve was performed on six isolates of S. oralis from infective endocarditis, two from septicaemia patients and two from the oral flora of normal individuals. Conclusion: Synercid showed superior bactericidal activity when compared to penicillin and vancomycin against all ten isolates of S. oralis tested. Synercid was bactericidal (99.9% kill) against all ten isolates of S. oralis within six hours of contact.
Publication details
- DOI
- 10.18295/2075-0528.2143
- Journal
- Sultan Qaboos University Medical Journal, 2(1), 25-31
- Publisher
- Sultan Qaboos University
- Open access
- Gold open access
- License
- CC BY-ND 4.0
Cite this article
APA 7
M, R. A. (2025). In-vitro Activity of Synercid and related Drugs against Streptococcus Oralis Isolated from Septicaemia and Endocarditis cases. Sultan Qaboos University Medical Journal, 2(1), 25-31. https://doi.org/10.18295/2075-0528.2143
MLA 9
M, Rafay A. "In-vitro Activity of Synercid and related Drugs against Streptococcus Oralis Isolated from Septicaemia and Endocarditis cases." Sultan Qaboos University Medical Journal, vol. 2, no. 1, 2025, pp. 25-31. https://doi.org/10.18295/2075-0528.2143.
Chicago (author–date)
M, Rafay A. 2025. "In-vitro Activity of Synercid and related Drugs against Streptococcus Oralis Isolated from Septicaemia and Endocarditis cases." Sultan Qaboos University Medical Journal 2 (1): 25-31. https://doi.org/10.18295/2075-0528.2143.
Harvard
M, R. A. (2025) 'In-vitro Activity of Synercid and related Drugs against Streptococcus Oralis Isolated from Septicaemia and Endocarditis cases', Sultan Qaboos University Medical Journal, 2(1), pp. 25-31. doi:10.18295/2075-0528.2143.
Vancouver
M RA. In-vitro Activity of Synercid and related Drugs against Streptococcus Oralis Isolated from Septicaemia and Endocarditis cases. Sultan Qaboos University Medical Journal. 2025;2(1):25-31. doi:10.18295/2075-0528.2143
IEEE
R. A. M, "In-vitro Activity of Synercid and related Drugs against Streptococcus Oralis Isolated from Septicaemia and Endocarditis cases," Sultan Qaboos University Medical Journal, vol. 2, no. 1, pp. 25-31, 2025, doi: 10.18295/2075-0528.2143.